阿斯利康和礼来公司宣布其治疗早期阿尔茨海默病(AD)药物AZD3293的Ⅲ期临床试验已获FDA快通道审批认可。临床研究显示,该药可减少AD患者和健康志愿者脑脊液中β-淀粉样蛋白(Aβ)。该药是口服β-分泌酶(BACE)抑制剂,BACE与Aβ的产生有关,抑制BACE可预防Aβ斑块的形成,有助于减缓或阻止AD AstraZeneca and Eli Lilly and Company announce that their Phase III clinical trial of AZD3293, an early treatment of Alzheimer’s disease (AD), has been approved by the FDA for fast-track approval. Clinical studies have shown that the drug can reduce β-amyloid (Aβ) in cerebrospinal fluid of AD patients and healthy volunteers. The drug is oral β-secretase (BACE) inhibitor, BACE and Aβ production, inhibition of BACE can prevent the formation of Aβ plaque, help to slow down or stop the AD